TSVT Stock Overview
A cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for TSVT from our risk checks.
2seventy bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.52 |
| 52 Week High | US$6.40 |
| 52 Week Low | US$1.54 |
| Beta | 1.79 |
| 11 Month Change | -29.46% |
| 3 Month Change | -25.11% |
| 1 Year Change | 102.30% |
| 33 Year Change | -89.45% |
| 5 Year Change | n/a |
| Change since IPO | -74.44% |
Recent News & Updates
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report
Nov 15
There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues
Oct 03Recent updates
Analysts Have Been Trimming Their 2seventy bio, Inc. (NASDAQ:TSVT) Price Target After Its Latest Report
Nov 15There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues
Oct 032seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues
Jul 04Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term
May 112seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround
Apr 03These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts
Mar 072seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%
Feb 06Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation
Jan 172seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth
Dec 13Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts
May 05Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%
Mar 212seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates
Mar 19We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate
Oct 042seventy Bio: This Spinoff In The CAR-T Space Is Attractive
Sep 082seventy bio Prospects
Aug 23Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook
Aug 12Shareholder Returns
| TSVT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.5% | -10.3% | -2.1% |
| 1Y | 102.3% | 13.6% | 29.6% |
Return vs Industry: TSVT exceeded the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: TSVT exceeded the US Market which returned 29.6% over the past year.
Price Volatility
| TSVT volatility | |
|---|---|
| TSVT Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TSVT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TSVT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 274 | Chip Baird | www.2seventybio.com |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company.
2seventy bio, Inc. Fundamentals Summary
| TSVT fundamental statistics | |
|---|---|
| Market cap | US$181.59m |
| Earnings (TTM) | -US$94.55m |
| Revenue (TTM) | US$45.62m |
4.0x
P/S Ratio-1.9x
P/E RatioIs TSVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSVT income statement (TTM) | |
|---|---|
| Revenue | US$45.62m |
| Cost of Revenue | US$136.35m |
| Gross Profit | -US$90.73m |
| Other Expenses | US$3.82m |
| Earnings | -US$94.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.83 |
| Gross Margin | -198.88% |
| Net Profit Margin | -207.25% |
| Debt/Equity Ratio | 0% |
How did TSVT perform over the long term?
See historical performance and comparison